Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
EAI-432 offers a new approach to targeting mutant-EGFR driven non-small-cell lung cancer, say Dana-Farber researchers.
Adding chemotherapy to Tagrisso was associated with a nearly nine-month delay in disease progression—and more side effects.
Osimertinib led to a 51% improvement in survival, but some say the placebo group did not receive adequate treatment.
The oral targeted therapy led to a 51% improvement in survival for patients with EGFR-mutated non-small-cell lung cancer.
Immunotherapy was far more effective than targeted therapy in extending survival for people with certain kinds of advanced melanoma.
Tagrisso (osimertinib) was approved for non-small cell lung cancer patients with EGFR-positive tumors.
If your life depends on it, wouldn’t you want to know EVERYTHING that might help?
The survival improvement did not come at the cost of safety; the investigators saw no increase in serious side effects.
Precision medicine matches patients with the treatments most likely to work for them.
Osimertinib led to improved progression-free survival in people with common EGFR mutations.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.